基本資料

投資策略

此基金主要透過投資於環球的大至中型健康護理行業公司，以提供較高回報。

基金經理人

• Wilkin Scott
• 資歷 9年(2016-08-31 至今)

• Scott Wilkin was appointed co-head of the enlarged Global Equity team in 2025, following the merger of the Global Equity and Global Value teams. He is also Director of Research. He acts as Lead PM on a number of strategies while being overall responsible for driving and maintaining excellent research standards across the team.
  Scott was appointed Head of Global Equity in 2016, having proven himself as one of the strongest investors across Active equities in various research roles, culminating in being Director of Research in the US. 
  In 2012, Scott was promoted to the position of Director of Research (DOR) for the US Intrinsic Value equity team. In this role, Scott managed a team of six sector-based analysts and lead company and industry-level research. Scott was also the lead portfolio manager of the Intrinsic Value equity team's Global Healthcare and UBS Healthcare Long/Short strategies. 
  
  Prior to being named DOR and portfolio manager, Scott was a Senior Investment Analyst and Sector Head for the Healthcare analyst team. His responsibilities included fundamental company and industry-level research. 
  Before joining the firm in 2003, Scott spent seven years as a securities analyst covering the medical device industry, most recently as a managing director at SG Cowen. Scott started his career serving in various business development, strategic planning and market research roles in the specialty pharmaceutical and diagnostic industries.
  Scott is a member of the Investments Committee to the board of the American Diabetes Association (ADA).

• Konosky Matthew
• 資歷 9年(2016-08-31 至今)

• Matthew Konosky is the Lead Healthcare Portfolio
  Manager and a Senior Investment Analyst on UBS Asset
  Management's US Intrinsic Value Equity Team. In his
  portfolio manager role, Matthew is Lead Portfolio
  Manager for the Global Healthcare Lux Fund as well as
  Deputy Portfolio Manager for the Global Biotech Lux
  Fund.
  Analyst responsibilities include fundamental company
  and industry-level research and development of
  company earnings models for the global
  pharmaceuticals and health care services sectors.
  Prior to joining the firm in 2006, Matthew worked as
  health care services analyst at Sanford C. Bernstein in
  New York and as a senior consultant at Mars & Co.
  serving several Fortune 500 health care clients.
  Matthew has also served as a member of the MIT
  Educational Counsel since 1997.

基金費用

聯絡資訊